Adam Shilling, PhD - President and Founder

Adam has over 23 years of pharmaceutical industry experience spanning all phases of clinical, regulatory and nonclinical drug development.  Adam advises several clients from large pharma to small biotech startup and is also part time Chief Development Officer at Nanocan Therapeutics.  Adam was most recently at Prelude Therapeutics where he built the regulatory department, was interim toxicology and clinical pharmacology lead, successfully opening several INDs. He also was study director for oral and IV programs, leading 3 clinical trials in solid tumors and hematologic malignancies. Before Prelude, Adam was at Incyte where he led the NDA submission and approval of Jakafi in acute GVHD and contributed to development and NDA/MAA approvals for Jakafi in myelofibrosis, polycythemia vera, Olumiant in rheumatoid arthritis, Tabrecta in NSCLC, Pemazyre in cholangiocarcinoma and Opzelura in atopic dermatitis. Prior to Incyte, Adam contributed to programs in infectious diseases, women's health and neuroscience at Wyeth (now Pfizer), including NDA for Pristiq in major depressive disorders.